EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.
Tang S, Huang T, Tang R, Lin K, Luo C, Shen Y, Zhang K, Tang Y, Kong J, Chen Z, Fu J, Lin Q, Guo L, Wu Y, Li Y, Zhang J, Sun Z, You P, Zhang D, Chen Y, Lin X, Zhong C, Lin Z, Liu H, Huang Z, Zhou W, Dong P, Liu X, Zeng H, Qi X, Zeng Y
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.